Journal
MOLECULAR MEDICINE REPORTS
Volume 16, Issue 5, Pages 6882-6889Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/mmr.2017.7455
Keywords
prolyl hydroxylase 3; hypoxia-inducible factor-1 alpha; vascular endothelial growth factor; gastric cancer; tumor suppressor
Categories
Funding
- Medicine and Health Research Foundation of Zhejiang Province [2012KYB016, 2011KYA069]
- National Key Basic Research Program of China [2014CB542101]
- Zhejiang Provincial Natural Science Foundation of China [LY14H100003]
Ask authors/readers for more resources
Prolyl hydroxylase 3 (PHD3) is widely accepted as a tumor suppressor; however, the expression of PHD3 in various cancer types remains controversial. The present study aimed to investigate the association between PHD3 expression and the clinicopathological features of gastric cancer using reverse transcription-quantitative polymerase chain reaction and immunohistochemistry. The effects of PHD3 in gastric cancer cell lines were assessed using western blot analysis and transwell migration assays. The present results revealed that PHD3 expression was increased in adjacent non-cancerous tissue compared with in gastric cancer tissue, and PHD3 overexpression was correlated with the presence of well-differentiated cancer cells, early cancer stage classification and the absence of lymph node metastasis. In vitro experiments demonstrated that PHD3 may act as a negative regulator of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor, both of which participate in tumor angiogenesis. In conclusion, the present results suggested that PHD3 may act as a tumor suppressor in gastric cancer. Therefore, the targeted regulation of PHD3 may have potential as a novel therapeutic approach for the treatment of patients with gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available